Mizokami Y, et al. - This research aspired to evaluate the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. In patients receiving long-term NSAIDs in double-blind (DB), the non-inferiority of vonoprazan (10 and 20 mg) was verified. With a safety profile similar to lansoprazole (15 mg), it was effective and well tolerated in extension study (EXT) for longer than 1 year.